JP2021522784A5 - - Google Patents
Info
- Publication number
- JP2021522784A5 JP2021522784A5 JP2020560920A JP2020560920A JP2021522784A5 JP 2021522784 A5 JP2021522784 A5 JP 2021522784A5 JP 2020560920 A JP2020560920 A JP 2020560920A JP 2020560920 A JP2020560920 A JP 2020560920A JP 2021522784 A5 JP2021522784 A5 JP 2021522784A5
- Authority
- JP
- Japan
- Prior art keywords
- scvacv
- virus
- item
- clone
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024028557A JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
| JP2025151400A JP2025178289A (ja) | 2018-05-02 | 2025-09-11 | 合成キメラワクシニアウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862665973P | 2018-05-02 | 2018-05-02 | |
| US62/665,973 | 2018-05-02 | ||
| PCT/US2019/030486 WO2019213452A1 (en) | 2018-05-02 | 2019-05-02 | Synthetic chimeric vaccinia virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028557A Division JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522784A JP2021522784A (ja) | 2021-09-02 |
| JP2021522784A5 true JP2021522784A5 (https=) | 2022-05-12 |
Family
ID=68386164
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560920A Withdrawn JP2021522784A (ja) | 2018-05-02 | 2019-05-02 | 合成キメラワクシニアウイルス |
| JP2024028557A Pending JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
| JP2025151400A Pending JP2025178289A (ja) | 2018-05-02 | 2025-09-11 | 合成キメラワクシニアウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028557A Pending JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
| JP2025151400A Pending JP2025178289A (ja) | 2018-05-02 | 2025-09-11 | 合成キメラワクシニアウイルス |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12529036B2 (https=) |
| EP (1) | EP3788142A4 (https=) |
| JP (3) | JP2021522784A (https=) |
| CN (2) | CN121320271A (https=) |
| AR (1) | AR115069A1 (https=) |
| AU (1) | AU2019262149B2 (https=) |
| BR (1) | BR112020022181A2 (https=) |
| CA (1) | CA3099330A1 (https=) |
| MX (1) | MX2020011586A (https=) |
| SG (1) | SG11202010272PA (https=) |
| TW (1) | TW201946651A (https=) |
| WO (1) | WO2019213452A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| CA3168836A1 (en) * | 2020-02-03 | 2021-08-12 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| KR20220165731A (ko) * | 2020-02-26 | 2022-12-15 | 토닉스 파마 리미티드 | Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신 |
| EP4153228A4 (en) * | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| TW202227621A (zh) | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| JP2024505274A (ja) | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| WO2023168286A1 (en) | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| CN116042656A (zh) * | 2022-11-25 | 2023-05-02 | 中山大学附属第七医院(深圳) | 一种猴痘病毒mRNA疫苗及其制备方法与用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2787577A (en) | 1953-12-01 | 1957-04-02 | Lilly Co Eli | Stable smallpox vaccine |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| US20040014034A1 (en) * | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| US8541003B2 (en) | 2003-06-20 | 2013-09-24 | Protein Sciences Corporation | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
| WO2005028634A2 (en) | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2005103259A1 (en) | 2004-04-26 | 2005-11-03 | University Health Network | Sars-cov nucleocapsid protein epitopes and uses thereof |
| JPWO2006022215A1 (ja) | 2004-08-23 | 2008-05-08 | 財団法人ヒューマンサイエンス振興財団 | ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 |
| CN101020055B (zh) | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
| US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| FI20115914L (fi) * | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| WO2014166084A1 (en) * | 2013-04-10 | 2014-10-16 | Totbiopharm Shanghai R & D Center | Mutant vaccinia virus strains, uses thereof and method of producing the same |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| CN108135996B (zh) | 2015-08-11 | 2022-06-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| WO2017047089A1 (en) | 2015-09-16 | 2017-03-23 | Shin Nippon Biomedical Laboratories, Ltd. | Vaccine compositions |
| AU2017332367B2 (en) | 2016-09-21 | 2021-12-23 | Stephen H. Thorne | High mobility group box i mutant |
| JP2019535311A (ja) * | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| ES2702618B2 (es) | 2017-09-04 | 2019-10-31 | Inst De Salud Carlos Iii | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| CN112261951A (zh) * | 2018-05-02 | 2021-01-22 | 通尼克斯制药控股有限公司 | 包含合成嵌合痘苗病毒的干细胞及其使用方法 |
-
2019
- 2019-05-02 EP EP19796145.1A patent/EP3788142A4/en active Pending
- 2019-05-02 CN CN202510639606.8A patent/CN121320271A/zh active Pending
- 2019-05-02 JP JP2020560920A patent/JP2021522784A/ja not_active Withdrawn
- 2019-05-02 BR BR112020022181-3A patent/BR112020022181A2/pt unknown
- 2019-05-02 CA CA3099330A patent/CA3099330A1/en active Pending
- 2019-05-02 CN CN201980029677.9A patent/CN112543806B/zh active Active
- 2019-05-02 AR ARP190101165A patent/AR115069A1/es unknown
- 2019-05-02 AU AU2019262149A patent/AU2019262149B2/en active Active
- 2019-05-02 US US17/050,946 patent/US12529036B2/en active Active
- 2019-05-02 WO PCT/US2019/030486 patent/WO2019213452A1/en not_active Ceased
- 2019-05-02 MX MX2020011586A patent/MX2020011586A/es unknown
- 2019-05-02 SG SG11202010272PA patent/SG11202010272PA/en unknown
- 2019-05-02 TW TW108115290A patent/TW201946651A/zh unknown
-
2024
- 2024-02-28 JP JP2024028557A patent/JP2024051112A/ja active Pending
-
2025
- 2025-09-11 JP JP2025151400A patent/JP2025178289A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522784A5 (https=) | ||
| JP2019535311A5 (https=) | ||
| CA2421151C (en) | Modified vaccinia ankara virus variant | |
| Afonso et al. | The genome of swinepox virus | |
| US12365879B2 (en) | Synthetic chimeric poxviruses | |
| JP2023515582A5 (https=) | ||
| AU2002231639A1 (en) | Modified vaccinia ankara virus variant | |
| BR112020022181A2 (pt) | vírus vaccinia quimérico sintético | |
| JP2020188776A (ja) | 組換えオルフウイルスベクター | |
| Zhang et al. | Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain | |
| CN105829537A (zh) | 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体 | |
| JP2019528755A5 (https=) | ||
| JP2024535145A5 (https=) | ||
| CA2372709C (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| EP1594970B1 (en) | Recombinant mva and method for generation thereof | |
| CN101142319B (zh) | 基于使用修饰安卡拉痘苗病毒的疫苗 | |
| JP2021522789A5 (https=) | ||
| Wang et al. | Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain | |
| Kan et al. | Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit | |
| Li et al. | Deletion of multiple genes induces virulence reduction of vaccinia virus Tiantan strain | |
| JP7034818B2 (ja) | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 | |
| Spread | Genome Scale Evolution of Myxoma Virus | |
| Maksyutov et al. | Construction of a Candidate DNA Vaccine against Human Orthopoxvirus Infections | |
| Qin | Using genomic sequencing to explore vaccinia virus diversity, recombination and evolution | |
| Stanford et al. | The Th 1/Th 2 paradigm |